Fundraising Fox
Cambridge · Seed–Series A · 48 people tracked
Also known as FLAGSHIP PIONEERING, LLC · Flagship Ventures Management, Inc.
Find your way into Flagship Pioneering
Sign up to see every warm intro you have to Flagship Pioneering
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Flagship Pioneering team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Flagship Pioneering has spent over 25 years pursuing breakthroughs at the frontiers of science, aiming to make the seemingly impossible possible for the benefit of people and the planet. The firm emphasizes a culture of fearless exploration and discovery, building companies and pioneering advances that push the boundaries of knowledge. Its work is centered on both scientific breakthroughs and the people who drive them.
Source: firm website, verified Sep 29, 2026.
Team · 48 people
from the firm's website & curated & public directories
Founder mafia
The Flagship Pioneering mafia →48 people who came through Flagship Pioneering went on to found or lead other companies.
What they invest in
from 59 of 86 portfolio companiesBiotech ×41AI & Machine Learning ×28Deep Tech ×22Healthtech ×12Medical Devices ×11Digital Health ×7Enterprise Software ×6SaaS ×6
HQs:United States×30Spain×1Rwanda×1Sweden×1Singapore×1
Who they back
founder profiles across 16 portfolio companiesFounding team size:solo founder×62 founders×23 founders×24+ founders×6
Where their founders studiedfrom 10 founders with education data
McGill University ×2
What their founders studiedfrom 11 founders with field-of-study data
Life Sciences ×6Engineering ×3Business & Management ×2
Where their founders worked beforefrom 15 founders with career history
Rubius Therapeutics ×3Cibo Technologies ×2Codiakbio ×2Etiome ×2Generate Biomedicines ×2Harvard Medical School ×2Massachusetts Institute of Technology (MIT) ×2Sana Biotechnology ×2
backed the same founder in 2+ companies: 2 founders
Investments · 86 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 72024 · 32023 · 32022 · 42021 · 82020 · 12019 · 12018 · 32017 · 52015 · 42014 · 258 dated
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Matthew Henn(President and Chief Scientific Officer)inJohn Aunins(Executive Officer)inEric D. Shaff(Executive Officer)inDavid Cook(Executive Officer)inRoger J. Pomerantz(Executive Officer, Director)inRichard N. Kender(Executive Chair and Interim Chief Executive Officer)
Board seatDavid BerryNoubar Afeyan· per SEC Form D
Co-investorsRA CapitalSofinnova VenturesFidelity Investments
Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.
AI & Machine LearningBiotechDeep TechSomerville, US
Gevorg Grigoryan(Founder)inMichael Nally(Chief Executive Officer)inAvak Kahvejian(Founder)Geoffrey von Maltzahn(Founder)Molly Gibson(Founder)
Co-investorsAlumni VenturesARCH Venture PartnersMarch Capital PartnersAlaska Permanent Fund CorporationALTITUDE LIFE SCIENCE VENTURESAltitude Ventures Management, Llc+3 more
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Founder)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)inAlexander Schuth(Founder)
Co-investorsARCH Venture PartnersEcoR1 CapitalF-Prime CapitalForesite CapitalGV (Google Ventures)Flagship Ventures
Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.
Adrian Gottschalk(President and Chief Executive Officer)
Co-investorsXeraya CapitalBiotechnology Value FundDeerfield Management Company
TransMedics develops and sells the Organ Care System (OCS), a portable warm perfusion platform for preserving and assessing donor hearts, lungs, and livers outside the body prior to transplantation, along with the National OCS Program, an end-to-end organ procurement and logistics service for transplant centers that includes aircraft and ground transportation.
HealthtechAndover, US
Waleed H. Hassanein(Executive Officer, Director)inStephen Gordon(Executive Officer)
BoardEdwin M. Kania, Jr.(Director)David Abrams(Director)Joseph S. Lacob(Director)Travis Rhodes(Director)
Co-investorsAlta Partners
CIBO provides a software platform for designing, deploying, and measuring regenerative agriculture and conservation programs, including workflow automation, scientific modeling, impact reporting, and a network of advisors managing grower engagement.
AgTechAI & Machine LearningClimate TechSaaSCambridge, US
Bruno Basso(Co-Founder and Special Advisor)David Worn(Executive Officer, Director)inBarry Martin(Executive Officer)inRyan Richt(Executive Officer)inDale Sorensen(Executive Officer)Sunand Menon(Executive Chairman & CEO)in
Board seatIgnacio MartinezStephen BerensonNoubar Afeyan· per SEC Form D
Co-investorsGeneration Investment ManagementStage 1 Ventures
Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function.
AI & Machine LearningBiotechDeep Tech
Avak Kahvejian(Chairman (Founder / founding CEO))inMike(Chief Innovation Officer & Co-Founder)Jaclyn Dunphy(Co-Founder & Senior Director of Strategy and Research Operations)inMaria-Chiara Magnone(Chief Scientific Officer)in
Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties.
AI & Machine LearningBiotechDeep TechHealthtech
Lovisa Afzelius(Executive Chair & Founding CEO)inMichelle Werner(CEO)inJoanne Protano(President & Chief Financial Officer)inDave Hava(Chief Scientific Officer)inNerissa Kreher(Chief Medical Officer)inCaroline Köhrer(SVP, Discovery Platform)in
Apriori Bio applies AI/ML combined with biological insights to predict how viruses evolve and to design vaccines, assessing their expected performance before clinical trials.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsGlobal Health Investment Corporation
Cloud ComputingData & InfrastructureEnterprise SoftwareAustin, US
Jonathan Ring(Executive Officer, Director)Paul Carpentier(Director)George Teixeira(Chairman of the Board, Co-founder)inJohn Bocskor(Former DataCore Vice President, Product Development and Co-founder)inMark Goros(Executive Officer, Director)Dave Zabrowski(Chief Executive Officer)in
Co-investorsInsight PartnersNew Science VenturesAdvantage Capital Partners
Etiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention.
AI & Machine LearningBiotechLongevity
Katharine von Herrmann(Co-founder)inAvak Kahvejian(Founding Team; Founding CEO)inNoubar Afeyan(Founding Team)inScott Lipnick(Founding Team)inTorben Straight Nissen(Founding Team; Board Director)inYann Echelard(Founding Team; Chief Operating Officer)
Inari applies artificial intelligence and gene editing to accelerate plant breeding, delivering crop improvement solutions for farmers focused on soybeans, corn, and wheat across broadacre agriculture.
AgTechAI & Machine LearningBiotechCambridge, US
Lisa Safarian(CEO)inStuart Brown(Chief Financial Officer)Pierre-Etienne Boin(Secretary and General Counsel)inPonsi Trivisvavet(President and Chief Executive Officer)inDavid Berry(Founder)
BoardRobert Berendes, Ph.D.(Director)
Co-investorsAcre Venture PartnersCongruent VenturesG SquaredCPP Investments
DataCore develops software-defined storage and object storage solutions for enterprises to virtualize and manage storage infrastructure across primary, secondary, and archive environments.
Cloud ComputingData & InfrastructureEnterprise Software
George Teixeira(Chairman of the Board, Co-founder)inJohn Bocskor(Co-founder, Former Vice President of Product Development)in
Co-investorsInsight PartnersPartners for GrowthPartners for Growth (PFG)Utiliti GroupAME Cloud Ventures
Metaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action.
AI & Machine LearningBiotechDeep TechMedical Devices
Co-investorsGlobal Brain
Montai is a drug discovery company that combines human biology, chemistry, computational biology, and machine learning to identify connections between chemistry and disease pathways and develop new therapies.
AI & Machine LearningBiotechDeep TechHealthtech
ProFound Therapeutics discovers and develops therapeutic candidates by analyzing the expanded human proteome, identifying novel proteins from previously uncharacterized genetic sequences that can serve as drug targets for cancer, immune disorders, and metabolic diseases.
AI & Machine LearningBiotechDeep Tech
Avak Kahvejian(Co-founder, Chairman)inYann Echelard(Co-founder)Vini Mani(Co-founder)inErica Weinstein(Co-founder)in
BoardNoubar Afeyanin
Co-investorsModi Ventures
Quotient is a biotechnology company applying somatic genetics research to R&D, developing its work through a proprietary platform.
AI & Machine LearningBiotechDeep Tech
Sail Biomedicines develops RNA-based medicines using a platform integrating Endless RNA and targeted nanoparticle delivery technology.
AI & Machine LearningBiotechDeep TechCambridge, US
John Mendlein(Executive Chairman)
Co-investorsNextech InvestQuan Capital
Terrana Biosciences is an agricultural biotech company applying RNA technology to plant health, developing a platform that gives crops new traits such as drought tolerance and shorter ripening times.
AgTechAI & Machine LearningBiotechDeep Tech
Noubar Afeyan(Founder)inIgnacio Martinez(Founder)inRyan Rapp(Founder & CEO)in
Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates.
AI & Machine LearningBiotechDeep TechCambridge, US
Yasir Al-Wakeel(CEO)in
Co-investorsARCH Venture PartnersSofinnova Ventures
BG Medicine develops and commercializes cardiovascular diagnostic tests to assess heart failure risk and predict cardiovascular events.
BiotechDigital HealthHealthtechMedical DevicesWaltham, US
Stephen Hall(Executive Officer)inPaul Sohmer(Executive Officer, Director)Aram Adourian(Executive Officer)Harry Wilcox(Director)Paul R. Sohmer, M.D.(President and CEO)
Board seatNoubar Afeyan· per SEC Form D · $2.5M raise · filed May 2015
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
BiotechSeattle, US
Doug Williams(Executive Officer, Director)in
BoardSteven Gillis(Director)Eric Lander(Director)
Board seatNoubar Afeyan· per SEC Form D
Co-investorsARCH Venture PartnersEcoR1 CapitalAlexandriaFidelity InvestmentsQatar Investment Authority
Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.
BiotechDeep TechMedical DevicesCambridge, US
Robert Langer(Founder)Noubar Afeyan, Ph.D.(Co-founder and Chairman, Moderna; CEO, Flagship Pioneering)Lorence Kim(Executive Officer)inJames R. Kasinger(Executive Officer)inStephen Hoge(Executive Officer)inDerrick Rossi(Founder)
Board seatNoubar Afeyan· per SEC Form D
Co-investorsAglae VenturesBlackstone Life SciencesFPVKhosla VenturesLingottoPremji Invest+5 more
BiotechCambridge, US
Torben Straight Nissen(Executive Officer, Director)inJoanne Protano(Executive Officer)inDavid Epstein(Director)Harvey F. Lodish(Director)Michael Rosenblatt(Director)Roger Pomerantz(Director)in
Board seatNoubar Afeyan· per SEC Form D
Co-investorsFlagship VenturesKendall Capital Partners
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Richard Mulligan(Director)inHans Bishop(Founder)Steve Harr(Founder)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)
.jpg?itok=YnNGtnt9)
Board seatGeoffrey von Maltzahn· per SEC Form D
Co-investorsAmerican Family VenturesARCH Venture PartnersCatalytic Impact FoundationF-Prime CapitalGV (Google Ventures)Innovating Capital+8 more
Ampersand provides a declarative integration framework for building bi-directional, customer-configurable product integrations with third-party applications.
Developer ToolsEnterprise SoftwareSaaS
Lauren Long(Founder)in
Co-investors2.12 AngelsMana VenturesMatrixFlex Capital Partners
Ampersand provides deposit administration services and operates as a national authority in the deposit management sector, serving depositors and financial institutions.
Enterprise SoftwareFintechSaaS
Co-investorsPatriot Financial PartnersJAM FINTOPFINTOP Capital
Ampersand builds electric motorcycles, battery packs, swap stations, and AmperOps fleet management software for motorcycle taxi (boda) drivers in Africa, operating a battery-swapping network for commercial e-motos.
CleantechEnergyMobility & Transportation
Co-investorsBeyond CapitalBeyond Capital VenturesBlue Haven InitiativeEcosystem Integrity FundFactor[e] VenturesAlphaMundi Group+2 more
Ampersand Biomedicines develops programmable, multi-specific biologic therapies designed to act only at the site of disease, aiming to reduce off-tissue side effects and toxicities.
AI & Machine LearningBiotechDeep Tech
BiotechHealthtechMedical DevicesWaltham, US
David F. Muller(Executive Officer, Director)inBrian J. Roberts(Executive Officer)inRhonda J. Bracey(Executive Officer)in
BoardJason Hong(Director)Jeff Dykan(Director)inAnthony Natale(Director)in
Co-investorsAPERTURE Venture PartnersLAVLilly Asia VenturesSCP Vitalife PartnersThird Point VenturesAbingworth+4 more
MIT is an educational and research institution in Cambridge, Massachusetts, pursuing teaching, research, and innovation across science, engineering, and other fields.
BiotechEdTechCambridge, US
Co-investorsBeyond Earth VenturesFoundersX VenturesJIMCOLair East LabsMassChallenge MexicoSelvedge Venture
Cellarity develops medicines using artificial intelligence and single-cell biology to address disease at the cellular level rather than targeting individual disease markers.
AI & Machine LearningBiotechDeep TechMedical Devices
Avak Kahvejian Nick Plugis(Founder)
Co-investorsAhren Innovation CapitalManta Ray VenturesBlackRock
Cloudflare provides a global cloud network platform delivering security, performance, and development services through sixty-plus integrated services including SASE, application security, and full-stack development infrastructure.
Cloud ComputingCybersecurityDeveloper ToolsSan Francisco, US
Matthew Prince(Founder)inMichelle Zatlyn(Co-founder and President)inLee Holloway(Founder)Dane Knecht(Chief Technology Officer)inThomas Seifert(Chief Financial Officer)inAlissa Starzak(Chief Legal Officer and Secretary)in
Co-investorsApposite CapitalCapitalGEQT Life SciencesEQT VenturesIcon VenturesIrregular Expressions+18 more
EVELO manufactures premium electric bikes designed for comfort and long-distance riding, sold direct-to-consumer with industry-leading warranty and support.
ConsumerDirect to ConsumerE-commerceHardwareMobility & TransportationSeattle, US
Yevgeniy Mordkovich(Executive Officer, Director)inBoris Mordkovich
Co-investorsForefront VentureAlexandriaGV (Google Ventures)Kaiser Permanente Ventures
BiotechCambridge, US
Jennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)inWilliam DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)
BoardNoubar B. Afeyan, Ph.D.(Director)
Co-investorsGV (Google Ventures)SV Health InvestorsAlexandriaKaiser Permanente VenturesMayo Clinic Ventures
Expedition Medicines is a drug discovery company applying artificial intelligence and covalent chemistry to design medicines targeting disease-driving proteins.
AI & Machine LearningBiotechDeep Tech
Harbinger Health develops early cancer detection technology through its Harbinger HX platform, which embeds developmental biology into biomarker discovery, assay design, and model training to detect faint biological signals of early cancer in real-world samples.
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsCatalyst
Inari builds insurance infrastructure technology platforms that enable insurers, MGAs, and reinsurers to operate more efficiently through AI automation and integrations.
AI & Machine LearningEnterprise SoftwareInsurTechSaaSBarcelona, ES
Frank Perkins(Chief Executive Officer)
Co-investorsCriteria Venture Tech
Parallel computing technology; acquired by Microsoft in 2009.
Co-investorsAscent Venture PartnersBantam Group
Kaleido offers a modular enterprise platform with pre-integrated products for tokenization, custody, digital assets, middleware, interoperability, and blockchain infrastructure.
Crypto & Web3Data & InfrastructureEnterprise Software
Steve Cerveny(Founder)inSophia Lopez(Founder)in
Co-investorsConsenSys MeshValor Capital GroupEQT Life SciencesInnovation IndustriesInvest-NLMenlo Ventures+1 more
Korrus makes the OIO System, a circadian lighting ecosystem consisting of smart bulbs, a spectral-control app, and a light sensor that shift light spectrum through the day to support focus and alertness and remove blue light at night to aid sleep.
ConsumerHardwareWellness & Fitness
Co-investorsEastward Capital PartnersRichmond Global Ventures
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)
Co-investorsAlpha Wave GlobalARCH Venture PartnersLAVLG Technology VenturesLilly Asia VenturesBaillie Gifford+3 more
LILA Sciences builds AI systems for autonomous scientific research and discovery across medicine, materials, energy, and defense sectors.
AI & Machine LearningBiotechDeep TechSaaS
Geoffrey von Maltzahn(CEO)Molly Gibson(Founder)Noubar Afeyan(Founder)
Co-investorsAlumni VenturesCatalio Capital Management, LPDauntless VenturesGeneral CatalystIn-Q-TelMarch Capital Partners+8 more
.png)
Co-investorsVantagePoint Capital Partners
Mirai Bio develops lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, combining cargo design, proprietary lipid chemistry, cell-specific targeting, in vivo evaluation, and manufacturability into a single development process.
AI & Machine LearningBiotechDeep Tech
Kate Torchilin(President & CEO)
Nobelprize.org provides open data about the Nobel Prizes and Nobel Laureates to developers through a REST API and as Linked Data (RDF/SPARQL).
Data & InfrastructureDeveloper ToolsEdTechImpact & Social GoodMedia & EntertainmentStockholm, SE
Novomer (part of Danimer Scientific) develops biodegradable and compostable materials used in everyday products such as packaging and straws.
BiotechCircular EconomyNew Materials
Co-investorsSaints CapitalAramco Ventures
Prologue Medicines develops therapeutics derived from viral proteins, using a computational platform to mine the viral proteome for proteins that can modulate human physiology and treat disease.
AI & Machine LearningBiotechDeep Tech
Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Torben Straight Nissen(Chief Executive Officer)inAnthony Coyle(President, Research and Development)inRobert Andtbacka(Chief Medical Officer)inJohn Delyani(Chief Business Officer)inJan Kisielow(Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.)in
Co-investorsSoftBank Vision FundJDRF T1D Fund
Ring provides video doorbells and security cameras that allow homeowners to monitor their property and enhance security across indoor and outdoor spaces.
HardwareIoT
Jamie Siminoff(Founder)in
Co-investorsAmerican Family VenturesCRV (Charles River Ventures)Energy Impact PartnersFelicis VenturesGreen Meadow VenturesGrishin Robotics+14 more
Ring Therapeutics develops vector-based targeted medicines using its Vectorology platform, which engineers conjugates derived from human commensal viruses to deliver diverse therapeutic payloads to specific tissues and cells.
BiotechDeep Tech
Chris McNulty(CEO)
Co-investorsBoutique Venture PartnersStage 1 Ventures
Serif Biomedicines develops DNA-based therapies and nucleic acid delivery technologies for genetic medicine.
BiotechDeep TechDigital HealthMedical DevicesCambridge, US
Jacob Rubens(Chief Executive Officer)in
Co-investorsModi Ventures
Seventh Sense develops face-based biometric authentication solutions that verify identity without storing facial data, serving organizations and individuals needing secure access control, document signing, and identity verification.
AI & Machine LearningCybersecurityDeep TechDigital HealthSingapore, SG
Ashish KushwahaSam TsuiVarun Chatterji
Co-investors500 GlobalFlagship VenturesNewpath Partners
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Terion operates an independent agricultural technology platform that turns field-level data, remote sensing, ecosystem models, and AI analytics into insights for crop planning, program enrollment, sustainability, and supply-chain traceability.
AgTechAI & Machine LearningSaaSBoston, US
Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases.
BiotechDigital HealthMedical Devices
Geoff von Maltzahn(Founder)inJoseph Romanelli(CEO)Geoffrey von Maltzahn(Founder)Jacob Rubens(Founder)Noubar Afeyan(Founder)Rob Citorik(Founder)
Co-investorsArtis VenturesMarch Capital PartnersOMX VenturesSoftBank Vision FundSolari CapitalToba Capital+5 more
Valo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields.
AI & Machine LearningBiotechHealthtech
David Berry(Founder)in
Co-investorsAtinum Investment Co. Ltd.BioGenerator VenturesHBM Healthcare InvestmentsHBM PartnersKoch Disruptive Technologies
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Pronutria BiosciencesAdvanced Electron BeamsAxcellaBlackDuckBoragenChamelicCIBOEmpress TherapeuticsGenerate BiosciencesIndigo AgricultureInvaioJoule Unlimited TechnologiesL NutraLarondeLS9Montai HealthOasys WaterPopulation Genetics TechnologiesSelventaSesen BioSeventh Sense BiosystemsSigilon TherapeuticsTorque TherapeuticsTrusted Network TechnologiesYourBio HealthZoī
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 11
8 IPOs · 3 acquisitions · showing 7Seres TherapeuticsNASDAQ: MCRBGenerate BiomedicinesNASDAQ: GENBDenali TherapeuticsNASDAQ: DNLIFoghorn TherapeuticsNASDAQ: FHTXTransMedicsNASDAQ: TMDXCaringoacq. by DataCoreAvedro, Inc.acq. by Glaukos
Portfolio news
latest coverage across their companiesProFound Therapeutics · prnewswire.com · Aug 27, 2026
Lila Sciences · finsmes.com · Jun 4, 2026
Harbinger Health · harbinger-health.com · Feb 27, 2026
Foghorn Therapeutics · globenewswire.com · Jan 10, 2026
Korrus · korrus.com · Jan 7, 2026
Extuitive · finance.yahoo.com · Sep 24, 2025
Terrana Biosciences · finsmes.com · Jul 3, 2025
Etiome · biospace.com · Apr 24, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Foghorn Therapeutics | 35.1% | $16.00 | Oct 2020 | $200.4M |
| TransMedics | 12.5% | $16.00 | May 2019 | $40.5M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ51 insider ownership filings (Forms 3/4/5)
at Generate Biomedicines, Inc. (GENB), Foghorn Therapeutics Inc. (FHTX), Sana Biotechnology, Inc. (SANA), Sigilon Therapeutics, Inc. (SGTX), Evelo Biosciences, Inc. (EVLO), Omega Therapeutics, Inc. (OMGA), Axcella Health Inc. (AXLA), Seres Therapeutics, Inc. (MCRB)
Files 13F institutional holdings reports · latest Aug 2026
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Flagship Pioneering made?
- Flagship Pioneering has 86 tracked investments, 11 of which have exited, including 9 dated in the last 24 months.
- What stage does Flagship Pioneering invest at?
- Flagship Pioneering invests at the Seed, Series A stages.
- What is Flagship Pioneering's typical check size?
- Flagship Pioneering typically writes checks of $500K – $10M.
- What sectors does Flagship Pioneering focus on?
- Flagship Pioneering focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Longevity, Sector Agnostic.
- Where is Flagship Pioneering located?
- Flagship Pioneering is headquartered in Cambridge, US.
- Does Flagship Pioneering lead rounds?
- Flagship Pioneering typically participates in rounds rather than leading them.
- Who does Flagship Pioneering co-invest with?
- Flagship Pioneering most often shares deals with ARCH Venture Partners, March Capital Partners, Modi Ventures, among 99 tracked co-investors.
Media · Podcasts & interviews
featuring the teamAvak Kahvejian of Flagship Pioneering at HLTH USA 2025
New York Stock Exchange · Avak Kahvejian
Yvonne Hao--Flagship Pioneering, Katie Rae--Engine Ventures & Anne Kelly at Evening with Ceres 2025
Ceres · Yvonne Hao
Flagship Pioneering's Noubar Afeyan speaks to new citizens at the JFK Library
John F. Kennedy Library Foundation · Noubar Afeyan
Fireside Chat with Noubar Afeyan, Founder & CEO of Flagship Pioneering
Boston Globe Events · Noubar Afeyan
No Priors Ep. 104 | With Flagship Pioneering CEO and Co-Founder Noubar Afeyan
No Priors: AI, Machine Learning, Tech, & Startups · Noubar Afeyan
Noubar Afeyan: Moderna, AI, Flagship Pioneering, Biotech, Armenia, Lebanon | Episode #007
MIT New Colossus Project · Noubar Afeyan
Images
Co-investors · 28
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.
▶16 more co-investors
Borealis VenturesLightspeed Venture PartnersSapphire VenturesSOSV23andMeTribeca Venture PartnersFlare Capital PartnersNational Grid PartnersTA VenturesJohnson & Johnson Innovation – JJDCCambridge Innovation Capital1955 Capital+ND CapitalVensana CapitalACORN BIOVENTURESPetri
Firms observed investing alongside Flagship Pioneering, from public investor directories. Shared companies are the overlap with Flagship Pioneering's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Draper Associates is a global early-stage venture capital firm that has funded transformative technology companies since 1985, backing founders across AI, crypto, healthcare, aerospace and other frontier fields.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Overwater Ventures is an early-stage venture firm that partners with pre-seed and seed stage founders working on large-scale problems, offering hands-on support across launch strategy, go-to-market, fundraising, and marketing.